ClinicalTrials.gg
WithdrawnNCT03297463Updated Aug 1, 2018

Radiation Therapy With Combination Immunotherapy for Relapsed/Refractory Metastatic Melanoma

A Phase 1/2 interventional study of Interleukin-2 & Ipilimumab (P-Ib) and Interleukin-2 & Ipilimumab (P-II) in Metastatic Melanoma, Pulmonary Metastases and Hepatic Metastases, sponsored by Masonic Cancer Center, University of Minnesota. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-08-01.

Sponsored by Masonic Cancer Center, University of Minnesota · Phase 1/2, Interventional, and Treatment

Why this study was withdrawn
Replaced by another study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
0
Allocation
Non-randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 43 studies testing Interleukin-2 in Melanoma — none open to participants now, 2 under way, none of them phase 3. Interleukin-2 · Melanoma.

Enrollment
36th of 41
0 · median 15
Started
2018
with 4 others
Phase 1/2
6 of 43
none open now
Registered
34th of 43
by date

Among the 43 studies testing Interleukin-2 in Melanoma, this one is the 36th largest by enrollment of the 41 interventional ones that give a count, is one of 5 that started in 2018, is one of 6 in phase 1/2, and was the 34th registered.

Melanoma

3,374 studies on the registry are indexed under Melanoma; 581 are open to participants now.

Browse Melanoma studies →

Open to participants now

None of the 43 studies testing Interleukin-2 in Melanoma is open now. The open studies under Melanoma, anywhere →

About Interleukin-2

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 468 Melanoma studies recruiting now, 381 (81%) set no upper age limit and 49 (10%) stop at 75 or younger; 47 take children under 18; 29 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 43 studies testing Interleukin-2 in Melanoma as a file.
02

Study summary

This is a Phase 1b/2 study designed to evaluate combination of the human T-cell cytokine Interleukin-2 (IL-2) and a checkpoint inhibitor Ipilimumab immediately following a course of hypofractionated palliative radiation therapy in the management of unresectable, relapsed/refractory metastatic melanoma.

Read the detailed description

The sequential administration of Interleukin-2 (IL-2) following radiation therapy offers a rational immunologic priming strategy to expand antigen primed T cells under the growth promoting effects of Interleukin-2 therapy.

This clinical trial is designed to evaluate the combination of the T cell cytokine Interleukin-2 and the checkpoint inhibitor Ipilimumab in sequential combination following a course of hypofractionated palliative radiation therapy. The addition of single dose Ipilimumab offers rational timing of CTLA-4 checkpoint blockade to decrease activity of regulatory and suppressor T cell subsets following IL-2 based immunotherapy.

03

Conditions studied

  • Metastatic Melanoma
  • Pulmonary Metastases
  • Hepatic Metastases
  • Brain Metastases
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • -proven unresectable, melanoma to standard immunotherapy drugs or regimens, including prior treatment with Aldesleukin (IL-2), GM-CSF, Ipilimumab, Nivolumab, Pembrolizumab, and/or Imlygic (T-VEC).
  • Prior clinical trial participation or treatment with molecularly targeted agents (i.e. Vemurafenib/Cobimetinib, Dabrafenib/Trametinib) or chemotherapy (i.e. Temozolomide, Dacarbazine, Platinum, or Taxanes) is permitted.
  • Must have a minimum of 3 radiographically distinct (>1.5 cm) lesions measurable by 1.1 at time of study enrollment (>5 preferred).

    • A maximum of 2 metastases per treated organ may be targeted for HD-XRT, but must be separated by more than 5 cm of normal tissue
    • At least 2 non-irradiated lesions are required for systemic response assessments
  • Pulmonary metastases: Pulmonary metastasis permissible. Appropriate candidates with lung lesions may be considered for ablative hypofractionation using SBRT.
  • Hepatic metastases: Hepatic metastasis permissible. Appropriate candidates with metastasis to liver may be considered for ablative hypofractionation using SBRT.
  • : Brain metastases may be treated using Gamma Knife Radiosurgery (GKR) or whole brain radiation therapy (WBRT) per the treating radiation oncologist. Total radiation dose and number of fractions will be determined by the treating radiation oncologist based on anatomic and dosing constraints. MRI of the vertebral column is required for all patients with suspected epidural tumor extension.
  • Must have sufficient archival tissue block material (1.5 x 1.5 x 1.5 cm) and/or newly obtained core or excisional biopsy of tumor tissue; minimum of 2 cores.
  • performance status 0 or 1 (appendix 2)
  • Age 18 to 85 years of age; > 85 years of age must be approved by Principal Investigator.
  • Adequate organ function within 14 days of registration (30 days for pulmonary and cardiac assessments) defined as:

    • Hematologic: Leukocytes ≥ 3,000/mcL, ≥ 1,000/mcL, ≥ 9.0 g/dL, ≥ 120,000/mcL
    • Renal: Serum creatinine ≤ 1.8 mg/dL; for patients with a creatinine > 1.5 mg/dL or a history of renal dysfunction, an estimated ≥ 35 mL/min/1.73 m2 is required
    • Hepatic: , ALT, and alkaline phosphatase ≤ 10 x and total ≤ 2.0 mg/dL Pulmonary: oxygen saturation ≥90% on room air; corrected DLCO and , ≥ 50% predicted
    • Cardiac: Absence of clinical decompensated congestive heart failure or uncontrolled arrhythmia; (echocardiogram within 6 months permitted) ≥ 40%. must be \< 450 ms in males and \< 470 ms in females.
  • Time from last anti-tumor treatment to first radiation treatment at least 1 week.
  • Recovery from previous cancer treatment (≤ Grade 1 by 4.0 criteria) prior to first radiation treatment
  • Women of and males with partners of childbearing potential must agree to the use of barrier methods of , hormonal contraceptives, or to abstain from heterosexual activity for the duration of study participation.
  • Ability to understand and provide voluntary written

Exclusion criteria

Exclusion Criteria:

  • Pregnant or breast feeding. The agents used in this study have the potential to harm a fetus. Radiation is a known teratogen. There is insufficient information regarding potential for fetal harm during immunotherapy at this time. Biological females of must have a negative serum pregnancy test within 14 days of registration.
  • Diagnosis of immunodeficiency
  • Concurrent use of high dose ; chronic steroid use of \< 2 mg dexamethasone or equivalent per day is permissible
  • Concurrent requiring active treatment, except basal cell carcinoma of the skin, squamous cell carcinoma of the skin or carcinoma in situ
  • Prior organ allograft or transplantation
  • disease
  • Uncontrolled intercurrent or psychiatric illness or social situation that would limit compliance with study requirements
  • within 30 days prior to the first dose of IL-2 and while participating in the trial. Examples of live vaccines include, but are not limited to, measles, mumps, rubella, chicken pox, yellow fever, rabies, BCG, and typhoid (oral) vaccine. Seasonal influenza vaccines for injection are generally killed virus vaccines and are allowed. However, intranasal influenza vaccines (eg, Flu - Mist®) are live attenuated vaccines, and are not allowed.
Terms in these criteria, in plain language(25)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Phase Ib (Dose Escalation)

    Drug: Interleukin-2 & Ipilimumab (P-Ib)

  • Experimental
    Phase II (Dose Expansion)

    Drug: Interleukin-2 & Ipilimumab (P-II)

Interventions

  • DrugInterleukin-2 & Ipilimumab (P-Ib)

    Drug pages: Interleukin-2 · Ipilimumab

    Phase Ib: - Ipilimumab will be administered in a 3 + 3 dose escalation design. * The starting dose will be 0.3 mg/kg administered within 7 days of day 1 cycle 2 ALdesleukin (IL-2). * If dose limiting autoimmune toxicities (DLTs) are not observed, the next cohort will receive 1.5 mg/kg. * The final cohort will receive 3 mg/kg, in the event that cohort 2 does not exhibit DLTs. * In the event of excessive toxicity in cohort 1, then a -1 dose level of 0.1 mg/kg may be evaluated in subsequent cohorts. Cohort sizes will increase to 6 patients if 1 of 3 patients in a cohort experience a DLT. * Once the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) is declared, no staggering of enrollment is required for accrual.

    Also known as: IL-2, Yervoy

  • DrugInterleukin-2 & Ipilimumab (P-II)

    Drug pages: Interleukin-2 · Ipilimumab

    Phase II: - Interleukin-2 \& Ipilimumab will be administered at the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D).

    Also known as: IL-2, Yervoy

06

What researchers measure

Primary outcomes

  1. Phase 1: Maximum Tolerated Dose (MTD)

    Incidence of Adverse Events

    Time frame: Cycle 2 Day 1

  2. Phase 1: Maximum Tolerated Dose (MTD)

    Incidence of Adverse Events

    Time frame: Cycle 2 Day 15

  3. Phase 1: Maximum Tolerated Dose (MTD)

    Incidence of Adverse Events

    Time frame: 30 days after last IL-2

  4. Phase 2: Objective Response Rate (ORR)

    Disease re-assessment includes physical examination, as well as radiographic response assessment (RECIST v1.1) of non-irradiated target lesions using CT (or PET/CT) and/or at MRI.

    Time frame: Day 35

  5. Phase 2: Objective Response Rate (ORR)

    Disease re-assessment includes physical examination, as well as radiographic response assessment (RECIST v1.1) of non-irradiated target lesions using CT (or PET/CT) and/or at MRI.

    Time frame: 30 days after last IL-2

Secondary outcomes

  1. Progression-free survival (PFS)

    Incidence of PFS

    Time frame: Every 3 Months until 2 Years from 1st IL-2 Dose

  2. Overall survival (OS)

    Incidence of OS

    Time frame: Every 3 Months until 2 Years from 1st IL-2 Dose

07

Study locations

1 site
  • Masonic Cancer Center - University of Minnesota
    Minneapolis, Minnesota 55455, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2018 (actual). Primary completion is estimated for Feb 2020, 24 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 26, 2017
First posted
Sep 29, 2017
StartActual
Jan 31, 2018
Primary completionEst.
Feb 1, 2020
CompletionEst.
Feb 1, 2020
Last update
Aug 1, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 1, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03297463
Responsible party
Sponsor
First posted
Sep 29, 2017
Start date
Jan 31, 2018
Primary completion
Feb 1, 2020 (estimated)
Completion
Feb 1, 2020 (estimated)
Last update
Aug 1, 2018

Study contacts

Domingo-Musibay Evidio, MD
principal investigator · Masonic Cancer Center, University of Minnesota

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jul 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Interleukin-2 · Ipilimumab

Start the discussion